Your browser doesn't support javascript.
loading
Fibrotic phenotype of IgG4-related disease.
Lanzillotta, Marco; Culver, Emma; Sharma, Amita; Zen, Yoh; Zhang, Wen; Stone, John H; Della-Torre, Emanuel.
Affiliation
  • Lanzillotta M; Università Vita-Salute San Raffaele, Milan, Italy; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Culver E; Oxford University Hospitals NHS Foundation Trust, University of Oxford, Oxford, UK.
  • Sharma A; Thoracic Imaging and Intervention Division, Massachusetts General Hospital, Boston, MA, USA.
  • Zen Y; Institute of Liver Studies, King's College Hospital and King's College London, London, UK.
  • Zhang W; Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China.
  • Stone JH; Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Della-Torre E; Università Vita-Salute San Raffaele, Milan, Italy; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: dellatorre.emanuel@hsr.it.
Lancet Rheumatol ; 6(7): e469-e480, 2024 Jul.
Article in En | MEDLINE | ID: mdl-38574746
ABSTRACT
A prompt response to glucocorticoids is a clinical hallmark of IgG4-related disease. However, manifestations characterised by prominent tissue fibrosis on histological examination can be less responsive to glucocorticoid therapy than other types of IgG4-related disease. These manifestations include retroperitoneal fibrosis, fibrosing mediastinitis, Riedel thyroiditis, orbital pseudotumor, and hypertrophic pachymeningitis, among others. To explain this discrepancy, a preliminary distinction into proliferative and fibrotic phenotypes of IgG4-related disease has been proposed on the basis of clinical presentation, pathological features, and response to immunosuppressive therapy. Implications of this classification for patient management remain an important area of investigation. In this Series paper, we aim to dissect the pathophysiology of tissue fibrosis in IgG4-related disease and discuss how clinicians should approach the management of fibrotic manifestations of IgG4-related disease based on the most recent diagnostic and therapeutic developments.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenotype / Fibrosis / Immunoglobulin G4-Related Disease Limits: Humans Language: En Journal: Lancet Rheumatol Year: 2024 Document type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenotype / Fibrosis / Immunoglobulin G4-Related Disease Limits: Humans Language: En Journal: Lancet Rheumatol Year: 2024 Document type: Article Affiliation country: Italy
...